0001171843-22-003636.txt : 20220512 0001171843-22-003636.hdr.sgml : 20220512 20220512163039 ACCESSION NUMBER: 0001171843-22-003636 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220512 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220512 DATE AS OF CHANGE: 20220512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Molecular Templates, Inc. CENTRAL INDEX KEY: 0001183765 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943409596 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32979 FILM NUMBER: 22918328 BUSINESS ADDRESS: STREET 1: 9301 AMBERGLEN BLVD STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78729 BUSINESS PHONE: 512 896 1555 MAIL ADDRESS: STREET 1: 9301 AMBERGLEN BLVD STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78729 FORMER COMPANY: FORMER CONFORMED NAME: THRESHOLD PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020828 8-K 1 f8k_051222.htm FORM 8-K Form 8-K
0001183765 False 0001183765 2022-05-12 2022-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  May 12, 2022

_______________________________

Molecular Templates, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-3297994-3409596
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

9301 Amberglen Blvd, Suite 100

Austin, Texas 78729

(Address of Principal Executive Offices) (Zip Code)

(512) 869-1555

(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par Value Per ShareMTEMThe Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 2.02. Results of Operations and Financial Condition.

On May 12, 2022, Molecular Templates, Inc. (the "Company") announced its financial results for the first quarter of 2022 ended March 31, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

99.1    Press release dated May 12, 2022
104     Cover Page Interactive Data File (embedded within the Inline XBRL document)

 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Molecular Templates, Inc.
   
  
Date: May 12, 2022By: /s/ Eric E. Poma, Ph.D.        
  Eric E. Poma, Ph.D.
  Chief Executive Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Molecular Templates, Inc. Reports First Quarter 2022 Financial Results

AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2022.

“We continue to make meaningful progress in advancing our pipeline of ETBs,” said Eric Poma, Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates. “We recently commenced dosing in Cohort 3 of our Phase 1 study of MT-6402 in PD-L1+ patients. We intend to report additional data from this study in the second half of the year. Dose finding in the MT-5111 and MT-0169 programs is ongoing with clinical data expected this year. We look forward to continued momentum across our pipeline in 2022, including filing an IND for MT-8421, our ETB targeting CTLA-4, and advancing our earlier stage pipeline of ETBs targeting TIGIT, TROP-2, and BCMA.”

Company Highlights and Upcoming Milestones

Corporate

  • MTEM expects to provide periodic updates on MT-6402, MT-5111, and MT-0169 throughout 2022.
  • MTEM hosted a webinar on MT-6402 (PD-L1 ETB with Antigen Seeding Technology) with David Spigel, M.D. of the Sarah Cannon Research Institute on April 13. A replay of the event (including slides) can be accessed here.
  • Abstracts on MT-6402 and MT-5111 (HER2 ETB) have been accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) annual meeting, to take place June 3-7, 2022, in Chicago, IL.
  • Gabriela Gruia, M.D. appointed to Board of Directors.
  • Megan Filoon promoted to General Counsel.

Immuno-oncology ETBs:

MT-6402 (PD-L1 ETB with Antigen Seeding Technology)

  • Patient enrollment continues in the Phase 1 study of MT-6402 which began in July 2021. MT-6402 is a 3rd generation ETB designed to induce potent anti-tumor effects via PD-L1 targeting through multiple mechanisms that may overcome the limitations of approved checkpoint inhibitors.
  • The Phase 1 study is a multi-center, open-label, dose escalation and dose expansion trial in the United States. Patients with confirmed PD-L1 expressing tumors or confirmed PD-L1 expression in the tumor microenvironment (TME) are eligible for enrollment.
  • As of March 2022, twelve patients with relapsed/refractory tumors that express PD-L1 have been treated to date across two dose cohorts: 16 mcg/kg (n=6) and 24 mcg/kg (n=6). Dosing continues with three patients currently enrolled in the 32 mcg/kg cohort (cohort 3).
  • One patient in cohort 1 (16 mcg/kg) with non-small cell lung cancer (NSCLC) that had progressed after prior checkpoint therapy (PD-1 and CTLA-4) had evaluable-only multiple sites of bone disease that appeared to have resolved on bone scan with only one remaining site which showed decreased uptake. This patient remained on MT-6402 up to cycle 8 when increased uptake was noted on bone scan and treatment was discontinued.
  • The 16 mcg/kg cohort was completed with no dose-limiting toxicities (DLTs) observed. One DLT was observed in a single patient in cohort 2 (24 mcg/kg). The patient experienced dermatitis that resolved rapidly with systemic steroids. The patient was rechallenged without incident at 24 mcg/kg. No other DLTs have been reported.
  • Following determination of the maximum tolerated dose (MTD), MTEM plans expansion cohorts to evaluate MT-6402 as a monotherapy in tumor-specific and PD-L1 positive basket tumor cohorts.
  • MTEM continues to observe pharmacodynamic (PD) effects including monocyte depletion and T cell activation in the 24 mcg/kg cohort. The extent and timing of these PD effects appear dose-related with patients in the 24 mcg/kg generally showing a more rapid and profound PD effect, including monocyte depletion and T cell activation, potentially in a dose-dependent manner.
  • These PD effects associated with immune activation were seen across the majority of patients irrespective of HLA type or level of tumor PD-L1 staining. The patient that demonstrated tumor regression was one of two patients treated with high tumor PD-L1 expression and may represent engagement of direct tumor cell-kill and antigen seeding.

MT-8421 (CTLA-4 ETB)

  • Preclinical data from MTEM’s CTLA-4 program were featured in a poster at the AACR annual meeting held April 8-13, 2022. In a transgenic mouse model expressing human CTLA-4 and bearing syngeneic subcutaneous tumors, MT-8421 treatment depleted immune suppressive regulatory T cells (Tregs) in the TME.
  • MT-8421 was well tolerated in a non-human primate toxicology study and achieved serum levels well-above projected IC50 concentrations for Tregs in the TME.
  • IND filing for MT-8421 is expected in 2H22, with clinical studies expected to commence in 2023.
  • MT-6402 and MT-8421 represent MTEM’s unique approach to immuno-oncology based on dismantling the TME through direct cell-kill of tumor and immune cells and not just the blocking of ligand-ligand interactions seen with current antibody therapeutics.

Research

  • MTEM continues to expand its unique approach to immuno-oncology targets with lead optimization on a TIGIT-targeting ETB on-going and additional exploration around new immuno-oncology targets.

Targeted Solid Tumor ETBs:

MT-5111 (HER2 ETB)

  • The Phase 1 study of MT-5111 in HER2-positive cancers is ongoing with multiple sites open for enrollment.
  • The HER2-positive breast cancer expansion cohort initiated in November 2021 at a dose of 10 mcg/kg.
  • As of January 2022, 30 patients had been treated with MT-5111 across eight dose escalation cohorts ranging from 0.5 mcg/kg to 13 mcg/kg without any DLTs. Enrollment in the 17 mcg/kg cohort has been initiated.
  • Dose escalation will continue to determine the MTD, while the breast cancer expansion cohort collects efficacy and safety data.
  • No signs of capillary leak syndrome (CLS) or significant cardiotoxicity have been observed to date with MT-5111.

Research

  • Lead optimization on a 3rd generation ETB targeting TROP-2 continues.

Hematologic Malignancy Targeted ETBs:

MT-0169 (CD38 ETB)

  • The revised protocol for the ongoing Phase 1 study in patients with relapsed/refractory multiple myeloma or non-Hodgkin’s lymphoma is now open. The revised protocol will explore a lower dose of MT-0169 to reduce the risk of adverse events observed at the initial dose and to enable patients to continue MT-0169 therapy for a longer duration that may drive tumor benefit. Importantly, the robust and rapid NK cell depletion that was observed at the starting dose is expected to be observed at lower doses.
  • MTEM is opening new sites for the Phase 1 study and anticipates enrollment beginning in the second quarter of 2022.

Research

  • Lead optimization on BCMA, SLAMF-7, and CD45 continues.

Financial Results

The net loss attributable to common shareholders for the first quarter of 2022 was $21.6 million, or $0.38 per basic and diluted share. This compares with a net loss attributable to common shareholders of $26.8 million, or $0.51 per basic and diluted share, for the same period in 2021.

Revenues for the first quarter of 2022 were $8.5 million, compared to $3.2 million for the same period in 2021. Revenues for the first quarter of 2022 were comprised of revenues from collaborative research and development agreements with Takeda and Bristol Myers Squibb.

Total research and development expenses for the first quarter of 2022 were $21.5 million, compared with $21.4 million for the same period in 2021. Total general and administrative expenses for the first quarter of 2022 were $7.6 million, compared with $8.2 million for the same period in 2021.

As of March 31, 2022, MTEM’s cash and investments totaled $124.5 million. MTEM’s current cash and investments are expected to fund operations to the end of 2023.

For more details on MTEM’s financial results for the first quarter 2022, refer to Form 10Q filed with the SEC.

About Molecular Templates

Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s Safe Harbor for forward-looking statements.  All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Molecular Templates may identify forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the safety or potential efficacy of Molecular Templates’ drug or biologic candidates, including the anticipated benefits of Molecular Templates’ next-generation ETBs; statements relating to the development of MT-6402, MT-5111, MT-0169, and MT-8421 and next-generation ETBs; the expected timing for submitting various IND applications and conducting studies, opening sites and generating data; the expected participation and presentation at upcoming conferences; the expected timing for providing updates on MT-6402, MT-5111, MT-0169, and MT-8421, including any pre-clinical data as well as Molecular Templates’ earlier stage pipeline of ETBs; Molecular Templates’ future cash needs and the length of time for which Molecular Templates’ cash resources are expected to be sufficient; the anticipated effects of the COVID-19 pandemic on Molecular Templates’ ongoing clinical studies, manufacturing and preclinical development; and Molecular Templates’ belief that its proprietary biologic drug platform technology, or ETBs, provides for a differentiated mechanism of action that may address some of the limitations associated with currently available cancer therapeutics.

Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process; whether Molecular Templates’ cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; Molecular Templates’ ability to timely enroll patients in its clinical trials; the ability of Molecular Templates’ to protect its intellectual property rights; risks from global pandemics including COVID-19; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in Molecular Templates’ filings with the SEC. There can be no assurance that any of Molecular Templates’ drug or biologic candidates will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Contacts:
Sean McLennan
Interim Chief Financial Officer
sean.mclennan@mtem.com 
512-334-6664

Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com 


Molecular Templates, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)

 Three Months Ended
March 31,		 
 2022  2021 
Research and development revenue, related party$—  $237 
Research and development revenue, other 8,486   2,983 
Total revenue 8,486   3,220 
Operating expenses:       
Research and development 21,497   21,368 
General and administrative 7,620   8,181 
Total operating expenses 29,117   29,549 
Loss from operations 20,631   26,329 
Interest and other income, net 70   52 
Interest and other expense, net (1,050)  (501)
Net loss 21,611   26,778 
Net loss attributable to common shareholders$21,611  $26,778 
Net loss per share attributable to common shareholders:       
Basic and diluted$0.38  $0.51 
Weighted average number of shares used in net loss per share
calculations:		       
Basic and diluted 56,305,049   52,564,628 

Molecular Templates, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)

 March 31,
2022(unaudited)		  December 31,
2021		 
ASSETS       
Current assets:       
Cash and cash equivalents$19,572  $24,983 
Marketable securities, current 104,947   118,061 
Prepaid expenses 2,615   3,917 
Other current assets 5,251   1,254 
Total current assets 132,385   148,215 
Marketable securities, non-current —   8,986 
Operating lease right-of-use assets 8,206   8,608 
Property and equipment, net 18,634   19,309 
Other assets 3,940   7,244 
Total assets$163,165  $192,362 
LIABILITIES AND STOCKHOLDERS’ EQUITY       
Current liabilities:       
Accounts payable$—  $1,612 
Accrued liabilities 7,905   9,515 
Deferred revenue, current 34,586   32,937 
Other current liabilities 2,533   2,606 
Total current liabilities 45,024   46,670 
Deferred revenue, long-term 24,252   33,350 
Long-term debt, net of current portion 35,737   35,491 
Operating lease liabilities 9,009   9,564 
Other liabilities 1,661   1,625 
Total liabilities 115,683   126,700 
Commitments and contingencies (Note 10)       
Stockholders’ equity       
Preferred stock, $0.001 par value:       
Authorized: 2,000,000 shares at March 31, 2022 and
December 31, 2021; issued and outstanding: 250 shares at
March 31, 2022 and December 31, 2021		 —   — 
Common stock, $0.001 par value:       
Authorized: 150,000,000 shares at March 31, 2022 and
December 31, 2021; issued and outstanding: 56,305,049 shares at
March 31, 2022 and 56,305,049 shares at December 31, 2021		 56   56 
Additional paid-in capital 421,386   417,704 
Accumulated other comprehensive loss (299)  (48)
Accumulated deficit (373,661)  (352,050)
Total stockholders’ equity 47,482   65,662 
Total liabilities and stockholders’ equity$163,165  $192,362 

 

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
May 12, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 12, 2022
Entity File Number 001-32979
Entity Registrant Name Molecular Templates, Inc.
Entity Central Index Key 0001183765
Entity Tax Identification Number 94-3409596
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 9301 Amberglen Blvd, Suite 100
Entity Address, City or Town Austin
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78729
City Area Code 512
Local Phone Number 869-1555
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 Par Value Per Share
Trading Symbol MTEM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 f8k_051222_htm.xml IDEA: XBRL DOCUMENT 0001183765 2022-05-12 2022-05-12 iso4217:USD shares iso4217:USD shares 0001183765 false 8-K 2022-05-12 Molecular Templates, Inc. DE 001-32979 94-3409596 9301 Amberglen Blvd, Suite 100 Austin TX 78729 512 869-1555 false false false false Common Stock, $0.001 Par Value Per Share MTEM NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_051222.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_051222.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_051222.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_051222.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_051222.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001171843-22-003636-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-22-003636-xbrl.zip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end